Study
| Phase II, open-label, multicenter study |
| Pretreated, HER2-positive, RAS wild-type, unresectable or metastatic colorectal cancer |
| Tucatinib + Trastuzumab q21 (n=117) |
Efficacy
| ORR: 38% [28-49] |
| DoR: 12.4 mos [8.5-20.5] |
Safety
| Any grade AEs: Diarrhea (33%), fatigue(20%), abdominal pain (20%) |
| Grade 3 AEs: ALT/AST increase (6.7% of both) |
Article no yet published
Tucatinib Plus Trastuzumab Active in Metastatic Colorectal Cancer
http://www.ncbi.nlm.nih.gov/pubmed/0
Reviewed by Elvin Chalabiyev, MD on Mar 15, 2023
